| |
EIB (n = 22)
|
TB-AOI (n = 20)
|
|---|
|
Female gender – no. (%)
|
17 (77)
|
11 (55)
|
|
Age – years
|
|
Median (IQR)
|
43 (8.3)
|
38 (17.8)
|
|
Country of origin – no. (%)
|
|
TB-HBC*
|
18 (82)
|
14 (70)
|
|
History of latent TB†− no. (%)
|
4 (18)
|
4 (20)
|
|
Duration of Symptoms – months (years)
|
n = 19
|
n = 15
|
|
Median
|
24 (2)
|
9 (0.8)
|
|
IQR
|
30 (2.5)
|
13 (1.1)
|
|
Diagnostics‡
|
|
TST
|
n = 16
|
n = 16
|
|
Range - induration (mm)
|
10–30
|
12–40
|
|
Median (IQR)
|
18 (7)
|
17.5 (7.8)
|
|
IGRA
|
n = 13 (7 had TST)
|
n = 15 (11 had TST)
|
|
Positive result – no. (%)
|
12 (92)
|
13 (87)
|
|
Chest X-ray
|
n = 22
|
n = 20
|
|
TB changes§ – no. (%)
|
4 (18)
|
1 (5)
|
|
Tissue Biopsy Pathology#
|
n = 17
| |
|
Granulomatous inflammation
|
15 (88)
|
No samples obtained for
|
|
Necrobiosis
|
9 (53)
|
pathology
|
|
Panniculitis
|
10 (59)
| |
|
Vasculitis
|
8 (47)
| |
- *TB-HBC = TB High Burden Country as per WHO classification [40]
- †TB history = reported prior exposure, documented TST conversion (positive after a prior negative), or prior LTBI therapy
- ‡TST = tuberculin skin test, IGRA = interferon-gamma release assay (QuantiFERON-TB Gold In-Tube Test)
- §TB changes (no.) = upper lobe calcification (2), multilobar ‘infiltrate’ (1), nodule (1), hilar lymphadenopathy (1)
- Pathology sums to > 100% as multiple patterns present in some specimens, No AFB or organisms seen in any samples
